Kamila Dymala, PharmD, MBA, BCMTMS, PACS

The ability to selectively silence or downregulate specific genes has opened new avenues for treating a myriad of diseases.

The potential for RNAi to offer targeted and sustained control of blood pressure may represent a transformative approach in the broader landscape of cardiovascular therapeutics.

As a CGRP receptor antagonist, zavegepant intervenes during the active phase of migraine, providing a targeted and prompt response to alleviate symptoms.

In December 2023, the FDA granted expanded indications for bempedoic acid and bempedoic acid plus ezetimibe in the treatment of primary hyperlipidemia.

Gepirone does not induce sexual dysfunction, a common limitation associated with SSRIs.

Available data indicate that as much as 50% of all antibiotics prescribed for individuals may be either unnecessary or not administered in the most effective manner as recommended.